Thailand’s HIV crisis is back after health chiefs revealed more than half a million people in the kingdom are living with the ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

Winning Founding Managing Editor and Executive Director of Cns (Citizen News Service) and Is a Feminist, Health and Development Justice Advocate.Scientific research has gifted us with a range of ...

Gilead said the price is comparable to existing HIV prevention drugs and the company will work with ... Peru, South Africa and Thailand. Schmid said the studies show people are much more likely to ...

As U.S. HIV/AIDS aid wanes, Thailand thrives with local leadership and community care — offering a model for others amid a global funding crisis.

"To end AIDS as a public health emergency we need a far stronger focus on prevention, and not just on keeping people living with HIV alive and well. New infections are like a leaking tap - "every drop ...

The Food and Drug Administration has approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.. The drug will be ...

The Centers for Disease Control and Prevention estimated in May that between 2018 and 2022, annual U.S. HIV transmissions declined by a modest 12%, from 36,200 to 31,800 cases.

A new way to prevent HIV infection is generating great buzz -- and more than a bit of controversy -- at this week’s AIDS 2024 Conference in Munich. The treatment consists of a twice-yearly ...

Two shots a year of a drug currently used to treat HIV infections were dramatically effective at preventing infections in a study among young women and adolescent girls in Africa.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections. FDA approves new twice-yearly HIV shot. What to know ...